Akoustis Technologies Inc (AKTS)

$0.04 0.00 (-9.05%)
Market Cap 5.75M
Revenue (ttm) 27.38M
Net Income (ttm) -167.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -613.40%
Debt to Equity Ratio 0.00
Volume 118,703,398
Avg Vol 26,170,799
Day's Range N/A - N/A
Shares Out 154.59M
Stochastic %K 6%
Beta 1.91
Analysts Sell
Price Target $1.00

Company Profile

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervi...

Industry: Biotechnology
Sector: Healthcare
Phone: 617-461-4023
Address:
17 Drydock Avenue, Suite 17-401, Boston, United States
RadioIsotope25
RadioIsotope25 Apr. 24 at 2:00 PM
$RADX ((data in June)) Strong data (≈90%) ✅ your base case What it means: Clearly better than MRI Clinically meaningful differentiation Opens door to: Acquisition Fast-track Phase 3 Valuation logic: RAD101 = $400–600M asset Add small therapeutic optionality 👉 Market cap: $300–500M 👉 Stock price: $25 – $42 $AKTS $CATX
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 24 at 1:57 PM
$RADX RADX is the only one where success is NOT priced in — and it's the closest to proving it. $AKTS $CATX
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 24 at 1:55 PM
$RADX Mispricing summary Company Expected Value Current Value Mispricing RADX ~$525M ~$60M ~9x undervalued AKTS ~$300M ~$1B ~3x overvalued CATX ~$140M ~$550M ~4x overvalued $AKTS $CATX
0 · Reply
STACKD0E
STACKD0E Apr. 23 at 4:21 PM
$CRBU $AKTS
0 · Reply
TargetSeeker6
TargetSeeker6 Apr. 22 at 3:10 PM
$AKTS where’s my props? Where’s my congratulations? Do you know how I achieved this? I married the daughter of the CEO. That’s how I got in so low that’s all you know. These Democrat politicians can do it. Why can’t the public! I highly recommend you go searching for a daughter of a father, who is very high up and a company and then marry her if you’re as good looking as I am
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 22 at 2:31 PM
There’s a value arbitrage of about $800 million between $RADX and $AKTS if you back out the cash balance of AKTS. RADX pipe is actually just as good or better. And there lead asset RAD101 could deposit a huge amount of cash onto RADX’s balance sheet if a deal is struck.
0 · Reply
STACKD0E
STACKD0E Apr. 22 at 1:31 AM
$CRBU $AKTS 🙃✨️
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 21 at 2:36 PM
$AKTS is on fire and $RADX has just as good or better radiopharmaceuticals and much deeper pipeline and backed by a premier radiopharma company Lantheus $LNTH
0 · Reply
k3n888
k3n888 Apr. 21 at 12:37 AM
$AKTS take note this is an Eli Lilly backed pharma company...
0 · Reply
TargetSeeker6
TargetSeeker6 Apr. 20 at 6:44 PM
$AKTS when should I take profits?
0 · Reply
Latest News on AKTS
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors

Apr 16, 2026, 8:00 AM EDT - 8 days ago

Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors

Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results

Mar 30, 2026, 4:01 PM EDT - 25 days ago

Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results

Aktis Oncology to Present at Upcoming March Investor Conferences

Feb 24, 2026, 4:05 PM EST - 2 months ago

Aktis Oncology to Present at Upcoming March Investor Conferences

Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

Feb 24, 2026, 8:00 AM EST - 2 months ago

Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 13, 2026, 6:30 AM EST - 3 months ago

Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets

Jan 9, 2026, 12:58 PM EST - 3 months ago

Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets

LLY

Aktis Oncology prices upsized US IPO at $18 per share

Jan 8, 2026, 9:20 PM EST - 3 months ago

Aktis Oncology prices upsized US IPO at $18 per share

Aktis Oncology Announces Pricing of its Upsized Initial Public Offering

Jan 8, 2026, 8:48 PM EST - 3 months ago

Aktis Oncology Announces Pricing of its Upsized Initial Public Offering

Aktis Oncology files for US IPO as biotech listings rebound

Dec 19, 2025, 5:51 PM EST - 4 months ago

Aktis Oncology files for US IPO as biotech listings rebound

Phase 1 solid tumor biotech Aktis Oncology files for a $100 million IPO

Dec 19, 2025, 5:51 PM EST - 4 months ago

Phase 1 solid tumor biotech Aktis Oncology files for a $100 million IPO

Aktis Oncology IPO Registration Document (S-1)

Dec 19, 2025, 4:02 PM EST - 4 months ago

Aktis Oncology IPO Registration Document (S-1)

RadioIsotope25
RadioIsotope25 Apr. 24 at 2:00 PM
$RADX ((data in June)) Strong data (≈90%) ✅ your base case What it means: Clearly better than MRI Clinically meaningful differentiation Opens door to: Acquisition Fast-track Phase 3 Valuation logic: RAD101 = $400–600M asset Add small therapeutic optionality 👉 Market cap: $300–500M 👉 Stock price: $25 – $42 $AKTS $CATX
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 24 at 1:57 PM
$RADX RADX is the only one where success is NOT priced in — and it's the closest to proving it. $AKTS $CATX
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 24 at 1:55 PM
$RADX Mispricing summary Company Expected Value Current Value Mispricing RADX ~$525M ~$60M ~9x undervalued AKTS ~$300M ~$1B ~3x overvalued CATX ~$140M ~$550M ~4x overvalued $AKTS $CATX
0 · Reply
STACKD0E
STACKD0E Apr. 23 at 4:21 PM
$CRBU $AKTS
0 · Reply
TargetSeeker6
TargetSeeker6 Apr. 22 at 3:10 PM
$AKTS where’s my props? Where’s my congratulations? Do you know how I achieved this? I married the daughter of the CEO. That’s how I got in so low that’s all you know. These Democrat politicians can do it. Why can’t the public! I highly recommend you go searching for a daughter of a father, who is very high up and a company and then marry her if you’re as good looking as I am
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 22 at 2:31 PM
There’s a value arbitrage of about $800 million between $RADX and $AKTS if you back out the cash balance of AKTS. RADX pipe is actually just as good or better. And there lead asset RAD101 could deposit a huge amount of cash onto RADX’s balance sheet if a deal is struck.
0 · Reply
STACKD0E
STACKD0E Apr. 22 at 1:31 AM
$CRBU $AKTS 🙃✨️
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 21 at 2:36 PM
$AKTS is on fire and $RADX has just as good or better radiopharmaceuticals and much deeper pipeline and backed by a premier radiopharma company Lantheus $LNTH
0 · Reply
k3n888
k3n888 Apr. 21 at 12:37 AM
$AKTS take note this is an Eli Lilly backed pharma company...
0 · Reply
TargetSeeker6
TargetSeeker6 Apr. 20 at 6:44 PM
$AKTS when should I take profits?
0 · Reply
TargetSeeker6
TargetSeeker6 Apr. 20 at 6:40 PM
$AKTS
0 · Reply
TargetSeeker6
TargetSeeker6 Apr. 20 at 6:02 PM
$AKTS all I hear is crickets?? no one on this board, giving me my props?
0 · Reply
TargetSeeker6
TargetSeeker6 Apr. 20 at 5:27 PM
$AKTS that’s how you do it.
0 · Reply
TargetSeeker6
TargetSeeker6 Apr. 20 at 5:26 PM
$AKTS read.
0 · Reply
TargetSeeker6
TargetSeeker6 Apr. 20 at 5:26 PM
$AKTS these are the perks of dating a daughter whose father is on the Board of Directors. You get in before the IPO.
0 · Reply
ArcherMagnum
ArcherMagnum Apr. 19 at 2:25 AM
$AKTS On March 30, 2026, the company announced FDA clearance for Investigational New Drug (IND) applications for its candidates AKY-2519 and AKY-1189. The latter also received Fast Track Designation for treating Nectin-4 positive tumors.
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 12 at 12:26 PM
$RADX https://youtube.com/shorts/G9QrVARx8q4?si=XA2hXyaAraQJWpob $AKTS $TLX $CATX $LNTH
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 12 at 1:58 AM
$AKTS $CATX $TLX $RADX
0 · Reply
DisneyPalaceTrades
DisneyPalaceTrades Apr. 10 at 5:49 PM
$AKTS
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 10 at 4:19 PM
$RADX Top 10 reasons why Lantheus should buy Radiopharm Theranostics. $LNTH $TLX $CATX $AKTS
0 · Reply
PHARMD09
PHARMD09 Apr. 8 at 3:48 PM
$AKTS
0 · Reply
PHARMD09
PHARMD09 Apr. 7 at 8:02 PM
$AKTS decent close. I’ll take it
0 · Reply